Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps battle blues: which TMS works best?

NCT ID NCT07181226

Symptom relief Sponsor: Krajská zdravotní, a.s. - Nemocnice Most, o.z. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two forms of transcranial magnetic stimulation (TMS) in 108 adults with major depression. Participants received either high-frequency or theta-burst TMS over two weeks. Researchers measured depression and anxiety before, after, and six weeks later to see which method worked better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS) device
What this could lead to
If successful, this could help doctors choose the best TMS method for treating depression and anxiety.
What could go wrong
This is a small, completed trial with only 108 participants. Results may not apply to everyone, and TMS can cause scalp discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

108 people

The number who actually took part.

Started

May 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 18 to 90 years. * Current major depressive disorder (MDD) as the primary diagnosis, confirmed according to the International Classification of Diseases, 10th Revision (ICD-10). * All participants had to be evaluated by a board-certified psychiatrist trained in rTMS to confirm eligibility. * Ability and willingness to provide written informed consent prior to study participation. Exclusion Criteria * Presence of ferromagnetic or electronic implants in the head or neck (e.g., pacemakers, aneurysm clips, cochlear implants, deep brain stimulators). * Known seizure disorders (such as epilepsy) or significantly increased risk of seizures. * Other major neurological diseases or conditions that would interfere with safe rTMS administration. * Active psychotic symptoms or a primary psychotic disorder. * Acute manic episode or recent hospitalization for mania or other severe psychiatric instability. * Ongoing electroconvulsive therapy (ECT) treatment. * Medication changes made during the study. * Inability to comply with the treatment schedule (e.g., attendance problems, logistical barriers). * Any medical or psychiatric condition judged by the investigators to compromise safety or data integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depression

Contacts and locations

Locations

  • Krajská zdravotní, a.s. - Nemocnice Most, o.z.

    Most, Ústí nad Labem Region, 434 64, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.